Genetic Testing Guidelines "Not Helpful" in Breast Cancer

International acclaim for new breast cancer treatment, Breast Reconstruction Fat Grafting.

The acceptance of clinical results at an eminent peer-reviewed forum like SABCS may be a strong validation of Niramai’s trial results. Artificial intelligence-based Indian health-tech company Niramai received international acclaim at the recent San Antonio breast cancer symposium (SABCS).
Genetic Testing
It was the only Indian company to present at one in every of the biggest breast cancer conferences within the world, well-attended by oncologists and cancer researchers.
India-based health tech company Niramai has received international acclaim at the recent San Antonio breast cancer symposium (SABCS). it had been the only Indian company to present at one of the largest breast cancer conferences in the world, which is well-attended by oncologists and cancer researchers.
The acceptance of clinical results at an eminent peer-reviewed forum like SABCS could be a strong validation of Niramai’s trial results. a chance to present the work to the international experts and receiving their positive feedback puts Niramai’s indigenous technology on the map beside leading innovations across the world.
At the conference, Niramai presented results of a retrospective multisite comparative study of 247 patients across 3 reputed cancer hospitals in Bharat. These demonstrated higher sensitivity and comparable specificity of the solution to mammography.
Dr Geetha Manjunath, CEO & CTO, Niramai, spoke about how their innovative solution uses artificial intelligence (AI) for detecting early stage breast cancer with results reminiscent of commonplace modalities. Niramai’s solution is called Thermalytix, an automated diagnostic tool, which combines thermal imaging with artificial intelligence. the solution is radiation-free, accurate, machine-driven and works on all women irrespective of their breast density. “We were privileged to get an opportunity to present at SABCS 2018, a prestigious forum for interaction and learning for a broad spectrum of medical practitioners, researchers and health professionals with a interest in breast cancer,” said Dr Geetha Manjunath.
US-based radiologists were receptive towards the solution, with, as an example, Dr Sheldon Feldman, a brand new York-based expert in breast surgery and surgical oncology, saying: “I am very intrigued by this promising technology. It’s like a major advance in technology. I hope to collaborate and be helpful to further validate its efficacy”.
This year, SABCS attracted more than 7000 participants from over 80 countries, as well as medical oncologists, radiation oncologists, researchers, and other healthcare professionals.
Previous
Next Post »

Need